Research Background

This study aims to develop a test that predicts nicotine dependence by simultaneously analyzing brain activity (MRI) and genetic information in smokers and non‑smokers. By linking the effects of nicotine on neural circuits with genetic factors, we seek to identify personalized smoking‑cessation strategies. This could represent a novel approach to improve the success rates of existing cessation therapies.

Clinical Design

Participants aged 18–55 are stratified into four cohorts: current smokers (with or without intention to quit), former smokers, and never‑smokers. Each participant undergoes six MRI scans combined with cognitive tasks. Smokers who intend to quit receive a 12‑week intervention comprising weekly counseling and e‑cigarette use. Scan time points are baseline (pre‑quit), 48 hours post‑quit, 2 weeks after e‑cigarette initiation, 5 weeks post‑quit, 6 months, and 1 year. The study commenced in November 2013 and has been completed.

Distinction from Current Smoking‑Cessation Therapies

Current cessation treatments rely primarily on nicotine replacement therapy (NRT), varenicline, bupropion, and behavioral counseling. However, therapies that incorporate individual genetic and neuro‑activity differences have not yet been commercialized. This study proposes a biomarker‑driven predictive model that could move beyond the one‑size‑fits‑all paradigm to deliver personalized treatment strategies.

Industry and Research Impact

If validated, the biomarker could enable pharmaceutical and digital‑health companies to invest in diagnostic kits and personalized drug development. Improved cessation success rates would also translate into reduced healthcare expenditures and broader public‑health benefits. Such data will provide critical evidence for building pipelines of therapeutics targeting smoking‑related diseases.